Analgesic Acute Pain Trials Should Assess Long-Term, Multi-Dose Safety
Executive Summary
Analgesic acute pain trails should assess long-term safety and multiple doses, members of FDA's Arthritis Advisory Committee suggested July 30
You may also be interested in...
Analgesic Comparative Trials Urged; Placebo Still Standard for Approval
FDA should encourage sponsors to conduct comparisons between standard analgesic therapies and newer agents, Arthritis Committee guest Mitchell Max, MD, National Institutes of Health, suggested
Analgesic Comparative Trials Urged; Placebo Still Standard for Approval
FDA should encourage sponsors to conduct comparisons between standard analgesic therapies and newer agents, Arthritis Committee guest Mitchell Max, MD, National Institutes of Health, suggested
Chronic Pain Standard Proposed By FDA Too Strict, Four Trials OK, Cmte Says
Global chronic pain can be an appropriate Rx analgesic indication, but the revised clinical trial requirements under consideration by FDA may be too stringent, Arthritis Advisory Committee members said